Topics

Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019

20:00 EDT 1 May 2019 | Globe Newswire

IRVING, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, May 9th, 2019 at 8:00 a.m. ET before the market opens.

The conference call will be accessible by dialing (844)348-3946 (toll-free domestic) or (213)358-0892 (international) using the access code: 5177169.  The webcast link is https://edge.media-server.com/m6/p/cwm9hw5f.

First quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://news.reatapharma.com and will be available for 12 months after the call.  The audio recording and webcast will be accessible for at least 90 days after the event through the Investors section of the company’s website at http://reatapharma.com.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.  Reata’s two most advanced clinical candidates, bardoxolone methyl (bardoxolone) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.  Bardoxolone and omaveloxolone are investigational medicines, and their safety and efficacy have not been established by any agency.

Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
http://reatapharma.com

Investors:
Vinny Jindal
Vice President, Strategy
(469) 374-8721
ir@reatapharma.com
https://reatapharma.com/contact-us/

Media:
Matt Middleman, M.D.
LifeSci Public Relations
(646) 627-8384
matt.middleman@lifescipublicrelations.com

Reata_TM_Logo-02.jpg

NEXT ARTICLE

More From BioPortfolio on "Reata Pharmaceuticals, Inc. to Report First Quarter 2019 Financials and to Provide an Update on Development Programs on May 9, 2019"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...